Future MS Market Landscape Explored by FirstWord in New Study Published at MarketPublishers.com
02 Oct 2012 • by Natalie Aster
LONDON – Multiple sclerosis (MS) is an autoimmune disease characterized by the body's own immune system attacking itself and causing spots of demyelination (plaques) in the brain and spinal cord. The most significant unmet need in MS is for therapies that either stop or reverse neuronal damage and/or offer improved symptom relief. However, there is still demand for new agents for treatment of relapsing remitting MS (RRMS) and for therapies with improved safety/tolerability/side effect profiles.
By the end of 2016, the global MS market is set to reach USD 17.3 billion. The growth will be mainly fuelled by the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and ongoing uptake of existing therapies.
New study “Consensus Outlook: Multiple Sclerosis” elaborated by FirstWord provides extensive analysis of the global MS market players and products of today and tomorrow, giving access to the following resources:
in-depth five-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance;
granular forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2006 to 2016;
timely event-driven market forecast report and data analysis updates over the next 12 months.
Consensus Outlook: Multiple Sclerosis
Published: September, 2012
Price: US$ 4.995,00
More Healthcare Equipment & Services Market Studies by FirstWord Include:
More new studies by the publisher can be found at FirstWord page.